Organization
EpicentRx
7 clinical trials
3 abstracts
Clinical trial
A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-08-11
Clinical trial
A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or OropharynxStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)Status: Completed, Estimated PCD: 2021-12-06
Abstract
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.Org: EpicentRx, Clinical Trials Innovations, Cleveland Clinic Lerner College of Medicine,
Clinical trial
A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line TherapyStatus: Terminated, Estimated PCD: 2016-05-10
Abstract
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap.Org: University of Texas MD Anderson Cancer Center, The Cleveland Clinic Foundation, City of Hope National Medical Center, EpicentRx, Mary Crowley Cancer Research Center,
Abstract
KEVLAR: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. standard of care in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).Org: EpicentRx, La Jolla, CA, Torrey Pines, CA, Clinical Trials Innovations, Mountain View, CA,